News of a new blood test that can accurately predict life expectancy has led to speculation that insurers could adopt the method to calculate premiums.
Existing guidelines from the Association of British Insurers (ABI) appears to rule out such a use of the new tests, however.
The blood test has been developed by Spanish firm Life Length, and will measure people's telomeres, which are thought to be linked to how long we live.
The test is to go on sale to the general public in the UK later this year and will cost £435.
Such a breakthrough in measuring life expectancy has sparked speculation that insurers could use the new method to help them with life insurance quotes.
It is possible that if firms were allowed to use the tests as a guide, people with short telomeres – thought to be linked to a lower life expectancy – could find themselves with high premiums or struggling to find cover at all.
However, an ABI guide for the public seems to suggest that insurance firms would be forbidden from demanding such information from consumers.
Under the ABI's 'Genetic tests and insurance: what you need to know' guide for consumers, it states:
In fact, the ABI document says that the only predictive test that must be declared to insurance companies is for Huntington's Disease for life cover worth more than £500,000.
The ABI has not yet confirmed whether or not the new tests could be allowed to be used by its member firms, and the body could not be contacted for comment.
Disclaimer: Information is correct as of the date of publication (shown at the top of this article). Any products featured may be withdrawn by their provider or changed at any time.
Moneyfacts.co.uk will, like most other websites, place cookies onto your computer’s
hard drive. This includes tracking cookies.